CTLA4 and hepatocellular carcinoma: Specifically, anti–CTLA‐4 therapy can deplete intratumoral regulatory T cells and promote de novo T cell priming [20], thereby reversing liver‐specific immune tolerance—a key immunologic barrier in HCC.